Open-label, non-randomized, parallel-group, multicentre clinical trial to evaluate the efficacy of fingolimod as therapy for de novo vs, fingolimod patients as therapy in patients previously treated with interferons or glatiámate acetate, based on the presence of outbreaks, in patients with recurrent relapsing multiple sclerosis
Trial Form Support, SL//Novartis Farmaceutica, S.A.
Pathology and candidate patients
Dr. Luís Martí Bonmatí
Hospital Quirónsalud Valencia.
January 17, 2012
Hospital Universitario La Fe
If you are interested in this clinical trial because you believe that you or a family member of yours can benefit from this new treatment.
You can request a consultation with the image diagnosis team by sending an email to the address: firstname.lastname@example.org